注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Agios Pharmaceuticals Inc是一家生物製藥公司。該公司在其基因定義疾病(GDD)產品組合中的主要候選產品PYRUKYND(Mitapivat)是一種野生型和多種突變型丙酮酸激酶(PK)酶的激活劑,用於治療溶血性貧血。Mitapivat是一種可口服的小分子,是丙酮酸激酶R(PKR)酶的有效激活劑。此外,該公司還在進行中的臨床試驗中評估米塔匹伐用於治療a-和b-地中海貧血和鐮狀細胞病(SCD)。該公司還在開發AG-946,一種PKR酶的臨床階段口服激活劑,用於治療溶血性貧血和其他適應症,包括SCD和與中低風險骨髓增生異常綜合徵(L-IR MDS)相關的貧血。該藥物處於I期臨床研究中。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jacqualyn A. Fouse | 61 | 2017 | Chair of the Board of Directors |
Shin-San Su | 67 | - | Co-Founder & Member of Scientific Advisory Board |
Lewis Clayton Cantley | 74 | 2007 | Co-Founder & Member of Scientific Advisory Board |
Tak Wah Mak | 77 | - | Co-Founder & Member of Scientific Advisory Board |
Craig B. Thompson | 70 | - | Co-Founder & Chairman of Scientific Advisory Board |
Brian M. Goff | 54 | 2022 | CEO & Director |
Kaye I. Foster-Cheek | 63 | 2014 | Lead Independent Director |
Scott A. Biller | 68 | 2010 | Member of Scientific Advisory Board |
Matthew Vander Heiden | - | 2008 | Member of Scientific Advisory Board |
David P. Schenkein | 67 | 2009 | Independent Director |
Marc Tessier-Lavigne | 64 | 2011 | Member of Scientific Advisory Board |
David T. Scadden | 71 | 2017 | Independent Director |
Cynthia Smith | 55 | 2022 | Independent Director |
Maykin Ho | 71 | 2015 | Independent Director |
Charles L. Sawyers | 65 | 2009 | Member of Scientific Advisory Board |
Ralph Deberardinis | - | - | Member of Scientific Advisory Board |
Joan S. Brugge | - | - | Member of Scientific Advisory Board |
Rahul D. Ballal | 46 | 2022 | Independent Director |
Jeffrey D. Capello | 59 | 2023 | Independent Director |
Catherine E. Owen | 53 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核